Arca
Skip to content
Tools
Tools

SMN2 pre-mRNA

Nucleic acid in Homo sapiens that 2 drugs act on.

  • Drugs that act on it: 2
  • Approved: 2
  • In phases 1 to 3: 0
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1
  • Other 1

Approved2

  • Nusinersen
  • Risdiplam

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        NusinersenApprovedBiogenOligonucleotidePositive modulatorSMN2 pre-mRNA positive modulator18
        RisdiplamApprovedRocheSmall moleculePositive modulatorSMN2 pre-mRNA positive modulator11

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 13 in all, from ClinicalTrials.gov.
        An Open Label Individual Patient (OLIP)-02 Study of Nusinersen (BIIB058)NusinersenPhase 3Not yet recruitingLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sSep 29, 2026
        An OLIP Study (Open Label Individual Patient) of Nusinersen in a Participant With Spinal Muscular Atrophy Who Previously Participated in an Investigational Study With NusinersenNusinersenNot applicableNot yet recruitingLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sSep 24, 2026
        A Registry of Cases of Spinal Muscular AtrophyNusinersen, Risdiplam—RecruitingSt. Jude Children's Research HospitalSep 4, 2026
        A Study of Risdiplam in Participants With Type I and Type II Spinal Muscle Atrophy (SMA)Risdiplam—RecruitingHoffmann-La RocheApr 15, 2026
        A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With RisdiplamRisdiplamPhase 3RecruitingBiogenMar 3, 2026
        Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1RisdiplamPhase 1 / Phase 2RecruitingGemma BiotherapeuticsJul 17, 2025
        A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular AtrophyNusinersen, RisdiplamPhase 2RecruitingScholar Rock, Inc.Jul 2, 2025
        Adult SMA Research and Clinical HubNusinersen, Risdiplam—RecruitingNewcastle-upon-Tyne Hospitals NHS TrustMay 18, 2025
        Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase IIINusinersenPhase 3Active, not recruitingGeneCradle IncMay 14, 2025
        Characterizing Perceived Physical Fatigability in Nusinersen-treated SMANusinersen—RecruitingColumbia UniversityMay 2, 2025
        A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)NusinersenPhase 1RecruitingBiogenAug 15, 2024
        Characterization of New Phenotypes of Patients With Spinal Muscular Atrophy Treated With SMN Restoring TherapyRisdiplamNot applicableRecruitingHospices Civils de LyonMar 20, 2024
        A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene TherapyRisdiplamPhase 4Active, not recruitingHoffmann-La RocheMay 17, 2023

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3826841, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.